Company intelligence / Profile preview

Eleven Therapeutics

Cambridge, England, United Kingdomeleventx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Eleven Therapeutics has developed proprietary high-throughput platforms to optimize the safety, efficiency, and duration of effect for next-generation mRNA/siRNA therapeutics. Their lead program—an intranasal siRNA targeting SARS-CoV‑2—is in preclinical development. The company’s pipeline also includes extended-release mRNAs for metabolic, hematologic, and infectious disease indications. No clinical results have been published as of May 2024.

Therapeutic areas: PulmonologyHematologyMetabolic DisordersInfectious Diseases
Modalities: mRNA therapeutics (including extended-release/xRNA)siRNARNAi-based drugs
Industry: Biotech

Partnerships

Supported by Bill & Melinda Gates Foundation; additional partners/funders not named but referenced as "valued partners"

Beyond the preview

Go deeper on Eleven Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eleven Therapeutics.

Explore the full profile